 CSL Limited recently closed a license agreement for a haemophilia B gene therapy candidate which is positive, but there are still risks associated with competition and regulatory approvals. The companys near-term outlook is mixed, with the potential upside of increased influenza vaccine demand offset by the prospects of low plasma collection volumes. 